



MAYNE PHARMA COMPLETES THERAPEUTICSMD PRODUCT LICENSING TRANSACTION

3 January 2023, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) today announces the completion of the exclusive product licensing transaction with TherapeuticsMD, Inc (TXMD), a NASDAQ listed company, which was announced on 5 December 2022.

Under the exclusive licence agreement Mayne Pharma has secured a portfolio of on-market women's health products from TXMD including three patent protected novel women's health products: ANNOVERA, IMVEXXY® and BIJUVA® and a portfolio of prenatal vitamins in the US as well as selected assets including inventory and regulatory filings to support the operation and commercialisation of the portfolio.

Under the terms of the agreement, Mayne Pharma paid a cash consideration to TXMD of US\$140m and a US\$13.1m payment for acquired net working capital and pre-paid royalties.

To fund the acquisition, Mayne Pharma used a combination of cash, existing debt facilities and a US\$27.95m convertible note to Rubric Capital Management LP.

Mayne Pharma's CEO Mr Shawn O'Brien said, "We are pleased to have completed this transaction which exclusively secures these highly complementary and patent protected women's health products in our portfolio. This transaction enables Mayne Pharma to strengthen our position in the attractive women's health therapeutic segment in the United States as well as continue to diversify our earnings.

Women's health is a core therapeutic area for Mayne Pharma and the addition of these products into our business is immediately accretive to earnings and supports our ambition to create a market leading position in the US women's health market".

For further information contact:

Craig Haskins

+61 421 029 843

ir@maynepharma.com

Authorised for release to the ASX by the Chair

ANNOVERA®, BIJUVA® and IMVEXXY® are registered trademarks of third parties

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia